Generic Name and Formulations:
Potassium (as bicarbonate and citrate) 10mEq, 20mEq, 25mEq; effervescent tabs for soln; unflavored, cherry vanilla, orange cream, lemon citrus, cherry berry flavors.
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Novel STAT3 Inhibitor Shows Some Anticancer Activity
- Osteoporosis Treatments
- Children's Vitamins Clinical Chart
- Breast Cancer (Invasive) Treatment Regimens
Indications for EFFER-K:
Hypokalemia with or without metabolic alkalosis. Digitalis intoxication. Hypokalemic familial periodic paralysis. Prevention of potassium depletion when dietary intake is inadequate.
Take with food or immediately after a meal; sip slowly over 5–10 mins. 1 tab 1–4 times daily, based on patient requirement. Dissolve each 10mEq tab in 2–3oz of cold water or juice (if unflavored); dissolve each 20mEq tab in 3–4oz of cold water or juice (if unflavored); dissolve each 25mEq tab in 4oz of cold water or 12–16oz of cold juice (if unflavored).
Hyperkalemia. Chronic renal disease. Metabolic acidosis. Uncontrolled diabetes mellitus. Esophageal compression. Delayed gastric emptying. Intestinal obstruction/stricture. Peptic ulcer. Concomitant potassium-sparing diuretics (eg, spironolactone, triamterene).
Discontinue if GI bleed, ulceration, or other disturbances occur. Acidosis. Renal or cardiac disease. Monitor serum potassium and magnesium levels, renal function, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with potassium-sparing diuretics, ACE inhibitors, NSAIDs, beta-adrenergic blockers, heparin, low-salt foods, potassium-containing drugs, digitalis glycosides, others.
Hyperkalemia, nausea, vomiting, abdominal discomfort, diarrhea.
Tabs 10mEq, 20mEq—30; 25mEq—30, 100 (orange-flavored)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML